Hypha Labs outlines developing platform for mushroom-derived ingredients
Hypha Labs has outlined its developing Mushroom Accelerator platform, which the company says is designed to produce mushroom-derived biological material in approximately eight days.
Hypha Labs, Inc. has described a developing biomanufacturing platform for mushroom-derived active ingredients. The company says its Mushroom Accelerator™ system is designed to produce biological material in approximately eight days, compared with the approximately 90-day conventional cultivation benchmark it cites.
Hypha Labs says the platform is intended to support faster and more consistent production through controlled bioreactor operations. Its developing commercial system also targets potential operational and production cost savings of up to 80%, which the company attributes to automation, lower labour requirements, a smaller production footprint and reduced biological waste.
The company’s proprietary Micropearls™ are described as biological starting material for downstream extraction and formulation. Hypha Labs says the resulting mushroom-derived active ingredients are intended for nutraceuticals, supplements, functional beverages and research applications.
Hypha Labs is working with Mycology Resources on commercial scale-up. The collaboration combines Hypha Labs’ production technology with mushroom genetics, analytical capabilities and extraction expertise, according to the company.
Hypha Labs says the stated objective is to develop a repeatable supply platform for manufacturers seeking consistent mushroom-derived ingredients. The company also says controlled production is designed to improve batch consistency and make downstream processing more predictable.
For industry context, Hypha Labs cited Grand View Research’s estimate that the global functional mushroom market will be $42.27 billion in 2026. Grand View Research projects the market to grow to $95.95 billion by 2033, according to the company.
Hypha Labs, Inc. is identified in the announcement as an OTCQB-listed company under the ticker OTCQB:FUNI. The company said its forward-looking statements are subject to risks and uncertainties described in its filings with the U.S. Securities and Exchange Commission.
Hypha Labs also stated that actual results may differ materially and that it does not undertake to update forward-looking statements except where required by law.
Hypha Labs is developing the Mushroom Accelerator™ platform for mushroom-derived biological material.
The company says the system is designed to produce material in approximately eight days, compared with an approximately 90-day conventional cultivation benchmark.
Hypha Labs’ developing commercial platform targets potential operational and production cost savings of up to 80%.
Micropearls™ are intended to provide starting material for ingredients used in nutraceuticals, supplements, functional beverages and research applications.
The company is collaborating with Mycology Resources on genetics, analytical work, extraction and commercial scale-up.
Hypha Labs, Inc. described its developing Mushroom Accelerator™ biomanufacturing platform for producing mushroom-derived active ingredients. The company said the platform is designed to accelerate production, improve consistency and reduce potential operational and production costs.
Hypha Labs, Inc. says its Mushroom Accelerator™ platform is designed to produce mushroom-derived biological material in approximately eight days. The company compares this with an approximately 90-day conventional cultivation benchmark.
Hypha Labs, Inc. says its developing commercial platform targets potential operational and production cost savings of up to 80%. The company attributes this potential to automation, reduced labour requirements, a smaller production footprint and minimised biological waste.
Hypha Labs, Inc. says its proprietary Micropearls™ provide biological starting material for downstream extraction and formulation. The resulting mushroom-derived active ingredients are intended for use in nutraceuticals, supplements, functional beverages and research applications.
Hypha Labs, Inc. says controlled bioreactor production is designed to improve batch consistency and make downstream processing more predictable. The company is developing automated mushroom production technologies intended to improve scalability, consistency and manufacturing efficiency.
Hypha Labs, Inc.'s collaboration with Mycology Resources combines the company's production technology with mushroom genetics, analytical capabilities and extraction expertise. The stated objective is to support commercial scale-up and provide a repeatable supply platform for manufacturers seeking consistent mushroom-derived ingredients.
Hypha Labs, Inc. targets nutraceuticals, supplements, functional beverages and research applications for its mushroom-derived active ingredients. The company's platform is intended to supply biological material for downstream extraction and formulation.
Hypha Labs, Inc. cited Grand View Research's estimate that the global functional mushroom market is $42.27 billion in 2026 and its projection that the market will be $95.95 billion by 2033. These figures were presented as market context for the company's developing production platform.
Hypha Labs, Inc. is identified in the announcement as trading on the OTCQB under the ticker symbol OTCQB:FUNI.
Hypha Labs, Inc. said its forward-looking statements are subject to risks and uncertainties described in the company's filings with the U.S. Securities and Exchange Commission. The company also stated that actual results may differ materially and that it undertakes no obligation to update forward-looking statements except as required by law.
Hypha Labs, Inc. directs investors to its current investor presentation at www.HyphaLabs.com/deck. The announcement also says the company may post new material information on its website or through its social media profiles.